Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233663 | 0.98 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| Methane SCHEMBL27085490 | 0.98 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL13711959 | 0.98 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| Bromide SCHEMBL6317924 | 0.98 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL15058848 | 0.95 | — | — | |
| SCHEMBL29102030 | 0.91 | — | — | |
| Formamide SCHEMBL28418050 | 0.87 | ALDH1A1 (0.47) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL25494359 | 0.86 | NPC1 (0.50) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL12744187 | 0.83 | NPC1 (0.48) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL972058 | 0.83 | HTR2C (0.45) | NPC1RAB9AMEN1HPGDGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | claimed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | claimed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | ABBVIE INC. | 2007-06-21 | — | — | US | claimed |
| US-7196200-B2 | Antibacterial compounds | ABBOTT LABORATORIES (US) | 2007-03-27 | — | — | US | claimed |
| US-20050159423-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | claimed |
| CN-1147493-C | Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analoges thereof | 3M | 2004-04-28 | — | — | CN | claimed |
| CN-1320126-A | Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2001-10-31 | — | — | CN | claimed |
| US-5364977-A | Chemical stabilization and powder processing | NIPPON SODA CO., LTD. (JP) | 1994-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPC1 123/4885RAB9A 1445/4885MEN1 582/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPC1 123/4885RAB9A 1445/4885MEN1 582/4885 |
| US-20070142353-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, FDPS, PGLS | NPC1 1886/4885RAB9A 1565/4885MEN1 3377/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPC1 123/4885RAB9A 1445/4885MEN1 582/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NPC1 174/4885RAB9A 1917/4885MEN1 473/4885 |
| US-20050159423-A1 | Antibacterial compounds | MRPL21, FDPS, PGLS | NPC1 1886/4885RAB9A 1565/4885MEN1 3377/4885 |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | NPC1 427/4885RAB9A 2215/4885MEN1 3502/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | NPC1 427/4885RAB9A 2215/4885MEN1 3502/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NPC1 174/4885RAB9A 1917/4885MEN1 473/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | NPC1 427/4885RAB9A 2215/4885MEN1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.